1 enrolling by invitation. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow IgA Nephropathy (IgAN): new trials by email Literature Review of IgA Nephropathy (IgAN) trials Research Report on IgA Nephropathy (IgAN)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept Atacicept 150 mg - IgA Nephropathy (IgAN), Renal and Urinary Disorders | Phase 2 | Enrolling by invitation | Vera Therapeutics, Inc. | 750 | 2024-12-01 | 2026-06-22 |
Glomerulonephritis, IGA (1) · Urologic Diseases (1)
Autoimmune Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nephritis (1) · Urogenital Diseases (1)
TACI receptor-IgG Fc fragment fusion protein (1)
United States (1)
Eric Michael, MD (1)